Lv1
20 积分 2022-07-31 加入
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
5天前
已完结
Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
5天前
已关闭
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
2个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
2个月前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
2个月前
已完结
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
4个月前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
4个月前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
7个月前
已完结
肿瘤免疫治疗相关肝损伤的研究进展
7个月前
已完结
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
7个月前
已完结
皖公网安备34019202002308
